Lilly rides Mounjaro, Zepbound to better
Time:2024-05-22 05:09:32 Source:sportViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:Joe Rogan's 'brain
Next:Sarah Jessica Parker divides opinion with enormous hat on set of And Just Like That
You may also like
- New York Liberty improve to 4
- Digital Audiovisual Art Fuels China's Culture, Tourism Consumption
- Students Learn About Intangible Cultural Heritages in Summer Vacation in Guangxi, S China
- Asian Games Torch Relay Highlights History, Vitality of Jiaxing
- OpenAI pauses ChatGPT voice after Scarlett Johansson comparisons
- Xinhua Headlines: China Speeds up Post
- Authorities Plan Major HPV Vaccine Drive
- Ninth Nishan Forum on World Civilizations Held in Qufu, E China
- Nigella Lawson, 64, reveals she would 'never take Ozempic' as a weight